MZEI DD MONEY TV LINKupdated Summary shareholder info for MZEI , August 6, 2010
https://medizoneint.com/
No FDA approval required!!!
Medizone International, Inc., a development stage company, engages in research into the medical uses of ozone. The company is seeking regulatory approval for MEDIZONE, a precise mixture of ozone and oxygen. Its MEDIZONE can be used as a therapeutic drug in humans to inactivate various viruses, and to treat various viral diseases, including human immunodeficiency virus, hepatitis B and C, Epstein-Barr, and herpes and cytomegalovirus, as well as to decontaminate blood and blood products, and to treat pathogenic conditions.
The company also focuses on the process of inactivating lipid-enveloped viruses for the purpose of decontaminating blood and blood products, as well as to assist the treatment of various diseases. In addition, Medizone International develops and acquires the related technology and equipment for the medical application of its Medizone Technology, the company's drug production and delivery system. The company, formerly known as Madison Funding, Inc., was incorporated in 1984 and is headquartered in Stinson Beach, California
https://www.secinfo.com/d13Vmp.s2s.htm
Profile Facts and Share Structure:
Float 180,000,000
Exchange OTCBB
Reporting Status Fully Reporting
Shares Authorized 395m / 50m preferred
Shares Issued / Diluted 239m (est)
Years in Business 23
If your are considering investing in Medizone this video is full of exciting news!!!
https://www.medizoneint.com/videoframe.html
Why Medizone?
• Medizone has a 23 year history in the field of medical therapeutics with Ozone.
• Medizone has initiated a joint program with Biozone Corporation to develop a state-of-the-art Ozone-based
sterilization system (AsepticSure™) for medical applications.
• This technology will feature a new “Ozone Destruct” scrubbing system intended to rapidly detoxify hospital working spaces following exposure to Ozone.
• The Medizone technology (AsepticSure™) will have an Ozone producing capacity 4 times greater than what is thought to be necessary under normal hospital circumstances.
• The AsepticSure™ system will also include a gas vaporization component, and a stand alone Ozone scrubbing system, adaptable to all hospital environments and space requirements.
Important news:
Medizone International Takes Aim at the Bioterrorism Countermeasures Arena
SAN FRANCISCO, Dec. 1 /PRNewswire-FirstCall/ -- Medizone International, Inc. (OTC Bulletin Board: MZEI) announced today that in tests involving its proprietary AsepticSure(TM) technology, it continues to break "6 log" decontamination barriers, this time with two very different spore forming bacteria, Claustridium difficile and Bacillis subtilis.
These results clearly establish AsepticSure(TM) as an extremely potent sporicidal technology. "The implications of a 6.7 log reduction (99.99997 %) in C difficile are indeed significant for the entire health care system," stated Dr Michael Shannon, Director of Medical Affairs for Medizone. "However, even though our findings for Bicillis subtilis are preliminary, the potential of being able to eliminate 99.999992% (7.2 log kill) of an internationally accepted surrogate for Anthrax in 90 minutes will have national security implications." In response to this news, Mr. Brad Goble, CEO of TDV GLOBAL and a Canadian leader in global health security and bio-terrorism countermeasures commented, "The international community continues to strengthen collaboration in the area of medical countermeasures, including placing a high priority on new and emerging technologies for decontamination.
Medizone's early laboratory results with Bicillis subtilis will attract great interest from the global defense and public health portfolios alike." Medizone believes that a field hardened variant of the AsepticSure(TM) hospital unit currently being readied for scale up testing will have wide bio defense applications internationally as it will be easily deployable in response to virtually any terrorist assault, extremely effective against a broad range of lethal pathogens, easy to manage and maintain and most importantly, it has the potential to save lives.
Medizone's CEO Edwin Marshall added, "Following the impressive results recently announced for MRSA, we immediately began to assess the capability of AsepticSure(TM) using the same updated technology with the spore forming bacteria C difficile, which is ubiquitous within hospitals and chronic care centers.
Following those results we then worked with Bicillis subtilis, which represents the infamous and highly lethal terrorist agent, Anthrax. In both cases, these two pathogens remain very resistant to standard decontamination procedures and hence, seeing our technology virtually annihilate these two difficult spore formers has lead Medizone to a parallel track of development with its AsepticSure(TM) technology which we are convinced will open up the possibility for commercialization in both arenas."
AsepticSure™ Eliminates Food-Borne Pathogens
San Francisco, California June 1, 2010. Medizone International, Inc. (MZEI.OB) announced another breakthrough today in its relentless pursuit to fully exploit the antimicrobial potential of AsepticSure™. Work just completed by its research team at Queen's University has now demonstrated the AsepticSure™ system can reliably eliminate in excess of 7 logs (99.99999%) of Listeria monocytogenes and Salmonella typhium with 30 minutes exposure to its unique and patented gas mixture.
"The CDC estimates that food-borne illness caused by these and other contaminants such as E coli affects 76 million people in the United States each year, leading to about 300,000 hospitalizations, and 5,000 deaths," stated Dr Michael Shannon, Medizone’s Director of Medical Affairs. "Although our main commercial thrust must remain focused on Hospital Acquired Infections, the list of very real applications for our system continues to grow. Deaths from food-borne illness in the United States remains a serious public health concern as it now accounts for more deaths on an annual basis than the cumulative military losses in Iraq since 2003 (4400). These are staggering statistics and in all conscience, cannot be ignored."
Medizone’s Chairman and CEO, Edwin Marshall added, “Our recent work with Listeria monocytogenes and Salmonella typhium was a direct result of a commercial inquiry from a cheese manufacturer who had recently suffered a multi-million dollar judgment against them related to these pathogens. Clearly the scope of our AsepticSure™ technology is vast and the commercial prospects nearly unlimited. With the anticipated start of our hospital beta test program imminent and the publication of peer reviewed journal literature on the science anticipated late summer, it is clear full commercialization is within view.
AsepticSure™ Eliminates Food-Borne Pathogens
San Francisco, California April 27, 2010.
In response to the growing need for the decontamination of sports training facilities and locker rooms from the Super Bug Methicillin-Resistant Staphylococcus Aureus, also known as MRSA, Medizone International, Inc. (MZEI.OB) is pleased to announce that it has successfully sterilized both naturally and artificially contaminated sports equipment using its highly versatile AsepticSure™ sterilization system. "The implications of these results are enormous to Medizone as the potential market for AsepticSure™ has at least quadrupled in size," stated Mr. Marshall, Medizone’s CEO.
As reported in a recent article entitled “Assessment of Athletic Facility Surfaces for MRSA in the Secondary School Setting” (Journal of Environmental Health, Feb., 2010) the authors stated that, "Methicillin-Resistant Staphylococcus Aureus (MRSA) was once largely a hospital-acquired infection, but increasingly, community-associated MRSA (CA-MRSA) is causing outbreaks among otherwise healthy people in athletic settings. Secondary school athletic trainers, student athletes, and the general student population may be at elevated risk of MRSA infection."
Part of the test program just completed by Medizone involved the evaluation of a hockey goalie’s glove used for three years by a 12-year-old Canadian boy. The inside surface of the glove was found to be heavily contaminated with MRSA along with a number of other less deadly pathogens.
March 16, 2010, Giant Step Forward for AsepticSure™
Medizone International Announces Giant Step Forward for AsepticSure™
San Francisco, March 16, 2010 Medizone International, Inc., (MZEI.OB) announces a giant step forward for the AsepticSure™ hospital sterilization system. Edwin Marshall, Medizone’s Chief Executive Officer explained, “A week ago we announced completing the first full round of room scale trials eliminating all pathogens across the ‘Super Bug’ spectrum on stainless steel surfaces. While it may seem counterintuitive, stainless is one of the more difficult surfaces to fully sterilize when contaminated with these highly resistant bacteria. Stainless also represents an FDA standard test surface. Today, we are announcing further developments that should have tremendous commercial implications relative to hospital acceptance of AsepticSure™ as the new standard in providing greatly enhanced patient safety.
Test results from our second stage of ‘room scale’ trials have clearly demonstrated that AsepticSure™ can reliably achieve 6 log (99.9999%) kill or greater on Porcelain and Formica as well as stainless surfaces. These materials represent the majority of all hospital surfaces. Utilizing a unique additional technology that is protected under our original patent filing of July 13, 2009, we have also demonstrated 6 log reductions with many common fabrics. Thus, it now appears the AsepticSure™ system is capable of decontamination to the previously unobtainable 6 log standard on all hospital surfaces, hard or soft.
Of commercial significance in a hospital setting, we are now able to greatly reduce the time required to achieve 6 log kills on hard surfaces to 30 minutes of exposure. With the charge time and destruct time for reuse of the space factored in, that translates to a room turn around time of 80 minutes, a 40 minute saving in total turn around time from our original target of 2 hours. Fabric exposure requires an additional 15 minutes to achieve the same 6 log kill rate, which represents a full turn around for a thorough cleaning of about 95 minutes for all surface materials.”
“This reduction in room turn around time from 120 minutes to 95 minutes for a thorough sterilization will be viewed very favorably by hospitals,” stated Dr. Michael Shannon, Medizone’s Director of Medical Affairs, who continued, “Any significant reduction in treatment time to put a room back into service is critical to hospital flow patterns. Given the sum of our results, it now appears that a typical protocol might have a hospital perform a first cleaning of 95 minutes to fully sterilize the space, which would be followed by cleanings, perhaps as infrequently as one time per week for lower risk settings, requiring only 80 minutes to complete. Not only is AsepticSure™ continuing to demonstrate its superlative antimicrobial efficacy, it is increasingly becoming apparent that it will be viewed as a practical necessity easily managed by trained hospital maintenance staff without putting rooms out of service for unacceptable periods of time.”
Chairman’s Message
Shareholder Update from the Chairman
June 28, 2010
Dear Shareholders,
In response to numerous requests for a progress report regarding our AsepticSure™ beta testing program, I wish to advise all interested parties that negotiations are well underway with a well known Ontario hospital. Our prototype decontamination system is fully prepared for deployment and subject to a final review for health and safety, full approval to begin beta-testing is soon expected without further delay.
While this review process by the Hospital Health and Safety Committee has taken longer than originally anticipated, this is a standard requirement when new devices are being introduced into a hospital environment. The hospital’s CEO and VP Medical Services have already approved the proposal using words such as “astonishing” and “imperative” to describe the technology.
In other on-going developments, the entire scientific and patent team have been working diligently for weeks now on preparation of a patent filing under the International Patent Cooperation Treaty (PCT). The filing will include both US patent application 61/223,219 titled “Healthcare Facility Disinfecting System” and US patent application 61/295,851 titled “Disinfecting Process and Apparatus.” As of January 14, 2010 142 member states had signed the PCT.
A complete list of member countries may be sourced at,
www.wipo.int/pct/guide/en/gdvol1/annexes/annexa/ax_a.pdf
Following recent International meetings being held in Canada, at one of which our Dr Michael Shannon made a presentation on the science behind AsepticSure™, the company can assure shareholders that our technology and the science behind it have now been brought into awareness at very high levels of government. Due to the sensitivity of some of the subject matter, shareholders should not expect any further information to be forthcoming for some time in this area.
I hope shareholders understand that progress is being made on many fronts. As specific milestones are met, we will announce them whenever possible.
Yours truly,
Ed
Edwin G. Marshall
Chairman of the Board
Chief Executive Officer
Board of Directors
Medizone International, Inc. Board of Directors
Edwin G. Marshall - Chairman of the Board and Chief Executive Officer
I hope shareholders understand that progress is being made on many fronts. As specific milestones are met, we will announce them whenever possible.
Yours truly,
Ed
Edwin G. Marshall
Chairman of the Board
Chief Executive Officer
Board of Directors
Medizone International, Inc. Board of Directors
Edwin G. Marshall - Chairman of the Board and Chief Executive Officer
Edwin G. Marshall became Chairman of the Board in June, 1997, following a successful hostile proxy takeover. He was additionally appointed Chief Executive Officer in April 1998. Mr. Marshall attended the College of Marin, with a double major in business and fire science. From 1964 to 1978, Mr. Marshall worked in the fire service in a city with a major chemical industrial complex, leaving with the rank of Captain. He then pursued various business interests including ownership of a real estate brokerage firm and part-ownership of a number of other small businesses in other fields. He has been a private investor in real estate, precious metals, and stocks since 1973.
Michael E. Shannon, M.A.,M.Sc.,M.D. - Board Member & Director of Medical Affairs
Dr. Shannon received his medical degree from Queen’s University in Canada, which included advanced training in surgery and sports medicine. He also holds post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for over 27 years. He served in the Canadian Forces for 31 years retiring at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for Canada. During the first Gulf War, Dr. Shannon served as the senior medical liaison officer for all of the Canadian forces. In 1996 he assumed responsibilities within Health Canada for re-organizing the Canadian blood system. Working with both the provincial and federal governments he oversaw the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. He was then appointed Director General for the Laboratory Centre for Disease Control, a position he held for three years. In December 2000, Dr. Shannon left the Canadian federal government to pursue a new career in industry. In that capacity he simultaneously directed a phase III clinical trial in Canada, the United States and Great Britain for an artificial blood substitute product. Following completion of that work he was asked to accept a special assignment with the Canadian Federal Government Auditor General’s office. His assignment being to conduct a cost benefit analysis of all government sponsored pharmacare programs and make recommendations directly to the Parliament of Canada. His assignment and presentation to Parliament was completed in November 2004. Dr. Shannon then served on a special assignment to the Canadian Public Health Agency (Center for Disease Control equivalent in the United States) as Senior Medical Advisor. His responsibility was to direct the rebuilding of the Emergency Medical Response Capacity for Canada. In this regard and under his direction, the largest emergency medical response exercise in the history of the country, involving the overnight construction of a mobile hospital, hundreds of doctors and thousands of patients, was successfully held in Toronto in December of 2007.
Dr. Shannon has been actively engaged in medical bio-oxidative (O3 based), research since 1987 and was directly responsible for the first human clinical trial to have ever been approved in North America which examined the efficacy of O3 delivered via minor autohemotherapy in the treatment of AIDS. He was also responsible for several primate studies utilizing O3 involving scientists from various departments within the Canadian Federal Government, as well as senior investigators from Medizone International and Cornell University. Dr. Shannon has served as the Senior Medical Advisor to Medizone International since 2002. In August of 2008 he accepted a position on the Board of Directors of Medizone International and assumed responsibility for medical affairs. In October 2008, he was additionally appointed the President of the Canadian Foundation for Global Health
annoted chart by redstick
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=52692220
Shareholder Update
August 4, 2010
The past few months have proven to be a fascinating time to be the CEO of Medizone International. It is clear to me that since the company's inception in 1986, the company has never been so perfectly positioned for previously unimagined levels of success.
In updating shareholders on progress since I wrote the June 28th Shareholder Update from the Chairman, the most direct way of putting it is by saying everything mentioned in that update has moved forward significantly.
Relative to government activity, on June 28th I had written, "Due to the sensitivity of some of the subject matter, shareholders should not expect any further information to be forthcoming for some time in this area." While that statement remains true today, and at this time we are not in a position to offer specifics, I must say that both Dr. Shannon and I, as well as the entire board of directors, could not be more pleased with both the level of interest being shown and supportive steps being initiated from very high levels of government, relative to the potentiality of AsepticSure™ and support for specific development programs.
On July 7th, the Patent Cooperation Treaty (PCT) filing was announced. The significance of that filing should not be underestimated. It represents the international cornerstone of intellectual property protection for AsepticSure™. In subsequent discussions with our lead patent attorney, additional filings have been suggested in order to build a very strong "patent fence" around our initial PCT application. The first of those filings may be anticipated later this year.
Shareholders have been inquiring when the hospital beta testing will start? Earlier, we had anticipated the start of beta testing before the end of June, with the first phase completed approximately mid-July, well before the August summer vacation period. Unfortunately, that time line simply did not work out. The various hospital committees required for approval took significantly longer than we had anticipated. Key members of both the hospital administration as well as our own staff in Canada, are now on their traditional summer holiday break until later in August. However, prior to vacations we overcame all hurdles and are now in full agreement on how to proceed. The process of identifying the progression of rooms to be sterilized and finalizing the actual in-hospital protocols to be used for this specific hospital is complete. These detailed preparatory steps are considered very important so that as we add additional beta-test sites in the US, we will have a good understanding of the most desirable and practical approach to use, thus saving time. In short, we have agreed to the start of beta testing the week after all key people have returned from vacation, the fourth week of August.
As I said at the beginning of these comments, it has been a fascinating time to be the CEO of Medizone. I feel blessed to have so many special people and institutions associated wi